- Trial phase
- Approved
- Time to market
- Approved and marketed since 2015 (first FDA approval Nov 2015)
- Why 4/10
- Tagrisso is already approved and commercially established with no pending PDUFA or pivotal readout in the next ~12 months. Its next binary catalyst was the Sept 2024 Stage III NSCLC approval, which has passed. As a mature blockbuster at a diversified pharma, there is no single hard dated event that would drive a dramatic share-price move, capping impactScore at 4 per the rubric.
Tagrisso is AZN's largest drug at $7.3B in 2025 revenue, but it is already fully de-risked and commercialized. The near-term investor debate centers on how quickly J&J's Rybrevant/lazertinib combo erodes first-line share and how far label expansion (LAURA Stage III) boosts volume, gradual commercial trends, not binary events. Watch quarterly sales growth rates and the LAURA OS readout for the next meaningful update.
Price Chart
Executive Summary
Tagrisso (osimertinib) is AstraZeneca's top-selling drug, generating ~$7.3 billion in 2025 revenue (~12% of AZN's total). It is a third-generation EGFR TKI approved across multiple lines of EGFR-mutated non-small cell lung cancer (NSCLC), from adjuvant early-stage through first-line metastatic and Stage III unresectable after chemoradiation. The drug faces a credible competitive threat from Johnson & Johnson's Rybrevant (amivantamab)/Lazcluze (lazertinib) combo, which showed superior overall survival in first-line NSCLC in the MARIPOSA trial. Patent protection extends to ~2032-2038. A US appeals court recently (July 2026) upheld a ruling in AZN's favor in a patent dispute with Pfizer. For a non-medical investor, Tagrisso is the mature, slow-growth cash cow of AZN's oncology portfolio, important but not a binary catalyst.
How It Works
Tagrisso is a targeted cancer pill (a third-generation EGFR inhibitor) that blocks a specific mutated protein on lung cancer cells, telling them to stop growing and dividing. It is designed to work against common EGFR mutations (exon 19 deletion, L858R) and also the T790M resistance mutation that develops after older EGFR inhibitors stop working.
Trial Status
Tagrisso is FDA-approved across multiple NSCLC indications: first-line metastatic (2018 full approval), adjuvant early-stage (ADAURA), with chemotherapy first-line (FLAURA2, Feb 2024), and unresectable Stage III after chemoradiation (LAURA, Sept 2024). The LAURA trial's overall survival data are still maturing. Multiple Phase 2/3 combination trials (with savolitinib, chemotherapy, novel agents) are ongoing.
The Two-Sided Case
Upcoming Catalysts
- LAURA Phase III overall survival (OS) readout, the trial is continuing to assess OS as a secondary endpoint; mature data could drive further label momentum
- Quarterly earnings reports, Tagrisso sales growth trajectory vs J&J competitive impact is a key investor focus
- Potential new combination trial readouts (savolitinib + osimertinib for MET-amplified NSCLC)
- Patent litigation developments, any future Paragraph IV challenges from generic manufacturers
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ASTRAZENECA PLC COURT-RULING AZN ·Originating report